-
A group of staphylococcal investigators from Lyon, France, and Houston, Texas, have been working for years to show the importance of toxins in the pathogenesis of S. aureus infections. The group of Jerome Etienne and Francois Vandenesch in Lyon have already shown the propensity of strains containing the PVL toxin to produce fatal necrotizing pneumonia in children.
-
Data collected by the Active Bacterial Core surveillance (ABCs) system in 2005 found that the incidence of invasive MRSA infections in patients undergoing dialysis was 45.2 per 1,000 population, an incidence far in excess of that estimated for the general population (0.2 to 0.4 per 1,000 population).
-
ACTG 328 was a multicenter trial that studied HIV-1 infected adults without active AIDS-defining illnesses and with CD4+ lymphocyte counts between 50 and 350/uL. Patients were protease inhibitor (PI) and IL-2 naïve but may have received prior nucleoside analogue therapy.
-
Since the publication of the initial IDSA Guidelines for the management of community acquired pneumonia in 2003, and their implementation by JHACO and the Centers for Medicare and Medicaid Services (CMS) in 2004 as a "quality standard" for hospital care and reimbursement, hospital administrators have been scrambling to improve their numbers.
-
The possible presence of 16 different respiratory viruses, including human bocavirus, was tested by quantitative polymerase chain reaction (PCR) (16 viruses), virus culture (9 viruses), and antigen detection (7 viruses) of nasopharyngeal aspirates and also acute- and convalescent-phase serologies (7 viruses) from 259 children (range, 3 months to 15 years; median age, 1.6 years) hospitalized for acute wheezing.
-
After a 2 year lull with few such reports, the CDC was informed of 10 cases of severe community-acquired pneumonia (CAP) due to MRSA in previously generally healthy individuals in Louisiana and Georgia in just the 2 months of December 2006 and January 2007.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
-
Hepatitis C virus (HCV) infection results in both acute and chronic hepatitis.
-
-